Search
Search
About
Log in
Join
Experiences with
Sipuleucel-T
Posts
Communities
33 public posts
Filter results
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer
These include combining Ra-223 with
sipuleucel
-
T
or immunooncology agents, to enhance immune responses, and trials in mildly symptomatic or asymptomatic patients. To date, the optimal timing, sequence, and combinations of Ra-223 with other agents are yet to be determined.
These include combining Ra-223 with
sipuleucel
-
T
or immunooncology agents, to enhance immune responses, and trials in mildly symptomatic or asymptomatic patients. To date, the optimal timing, sequence, and combinations of Ra-223 with other agents are yet to be determined.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
Therapy for metastatic CRPC includes abiraterone acetate, enzalutamide, docetaxel, cabazitaxel,
sipuleucel
-
T
, and radium-223. However, survival remains modest for men with progressive disease despite AR-targeted therapy and docetaxel, and therefore novel treatments are needed.
Therapy for metastatic CRPC includes abiraterone acetate, enzalutamide, docetaxel, cabazitaxel,
sipuleucel
-
T
, and radium-223. However, survival remains modest for men with progressive disease despite AR-targeted therapy and docetaxel, and therefore novel treatments are needed.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
Since then, the FDA has approved four other agents (enzalutamide, cabazitaxel, radium-223, and
sipuleucel
-
T
) on the basis of an OS benefit in metastatic prostate cancer. Promising data also exist for other investigational agents in progressive metastatic CRPC.
Since then, the FDA has approved four other agents (enzalutamide, cabazitaxel, radium-223, and
sipuleucel
-
T
) on the basis of an OS benefit in metastatic prostate cancer. Promising data also exist for other investigational agents in progressive metastatic CRPC.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
The interaction between radiation therapy and immunotherapy for PCa.
For example, while the Provenge (
sipuleucel
-
T
) vaccine is FDAapproved to treat prostate cancer, it extends survival by only months. Immune checkpoint inhibitors, such as those that target PD1/PD1L, can cause dramatic responses, but they do so in only a small proportion of patients.
For example, while the Provenge (
sipuleucel
-
T
) vaccine is FDAapproved to treat prostate cancer, it extends survival by only months. Immune checkpoint inhibitors, such as those that target PD1/PD1L, can cause dramatic responses, but they do so in only a small proportion of patients.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ProVent Trial Aims to Halt Disease Progression, Reduce Need for Prostate cancer treatment using provenge
Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced it will conduct a large-scale, placebo-controlled clinical trial evaluating the effectiveness of PROVENGE® (
sipuleucel
-
T
) in reducing disease progression in men
Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced it will conduct a large-scale, placebo-controlled clinical trial evaluating the effectiveness of PROVENGE® (
sipuleucel
-
T
) in reducing disease progression in men
Darryl
Partner
in
Advanced Prostate Cancer
6 years ago
Immunotherapy for Prostate Cancer: Where Do We Go From Here?—PART 1: Prostate Cancer Vaccines
Sipuleucel
-
T
Sipuleucel
-
T
consists of autologous peripheral blood–derived mononuclear cells cultured with a prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein.
Sipuleucel
-
T
Sipuleucel
-
T
consists of autologous peripheral blood–derived mononuclear cells cultured with a prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein.
JLS1
in
Advanced Prostate Cancer
6 years ago
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
The approval of the rst therapeutic anticancer vaccine,
sipuleucel
-
T
, by the Food and Drug Administration for the treatment of metastatic hormone-refractory prostate cancer in April 2010 has enforced a new era of immunotherapy (3).
The approval of the rst therapeutic anticancer vaccine,
sipuleucel
-
T
, by the Food and Drug Administration for the treatment of metastatic hormone-refractory prostate cancer in April 2010 has enforced a new era of immunotherapy (3).
JLS1
in
Advanced Prostate Cancer
6 years ago
Diagnosis + 18 years; update since Xofigo
Therapy 2011 PSA 3.5, to date Continuous (injections every 6 months) Eligard Androgen Deprivation Therapy 2012 PSA 1.7, -2013 PSA 1.8, Two Xgeva injections, then stopped Xgeva 2013 PSA 3.2, 10 days Palliative Radiation of Mets T7 thru T10 Vertebrae and left 10th rib, PSA .2 2014 PSA 1.29, 3 Provenge (
Sipuleucel
-
T
Therapy 2011 PSA 3.5, to date Continuous (injections every 6 months) Eligard Androgen Deprivation Therapy 2012 PSA 1.7, -2013 PSA 1.8, Two Xgeva injections, then stopped Xgeva 2013 PSA 3.2, 10 days Palliative Radiation of Mets T7 thru T10 Vertebrae and left 10th rib, PSA .2 2014 PSA 1.29, 3 Provenge (
Sipuleucel
-
T
chascri
in
Advanced Prostate Cancer
7 years ago
STAMPEDE - Zytiga at ADT initiation. NEJM Paper.
Several agents have improved overall survival (docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, radium-223, and
sipuleucel
-
T
)1-8 or reduced morbidity (zoledronic acid and denosumab)9-11 among such patients.
Several agents have improved overall survival (docetaxel, abiraterone acetate, enzalutamide, cabazitaxel, radium-223, and
sipuleucel
-
T
)1-8 or reduced morbidity (zoledronic acid and denosumab)9-11 among such patients.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Advanced Prostate Cancer: Research Update
New Treatment Vaccines You may have heard of
sipuleucel
-
T
(Provenge), a vaccine that uses your own white blood cells to destroy prostate cancer cells. Now, studies are underway to see if radiation, hormone therapy, or an experimental cancer vaccine called pTVG-HP helps Provenge work better.
New Treatment Vaccines You may have heard of
sipuleucel
-
T
(Provenge), a vaccine that uses your own white blood cells to destroy prostate cancer cells. Now, studies are underway to see if radiation, hormone therapy, or an experimental cancer vaccine called pTVG-HP helps Provenge work better.
motosue
in
Advanced Prostate Cancer
8 years ago
Common Treatments for Advanced Prostate Cancer
Sipuleucel
-
T
(Provenge) is used to treat advanced prostate cancer. To make it, the doctor removes white blood cells from your blood. These go to a lab, where experts genetically engineer them to fight your prostate cancer.
Sipuleucel
-
T
(Provenge) is used to treat advanced prostate cancer. To make it, the doctor removes white blood cells from your blood. These go to a lab, where experts genetically engineer them to fight your prostate cancer.
motosue
in
Advanced Prostate Cancer
8 years ago
Duration of Treatment ... with Abiraterone Acetate or Enzalutamide.
Weighted Kaplan-Meier and Cox proportional hazard models were used to compare the combined duration of mCRPC treatments (AA, ENZ, chemotherapy,
sipuleucel
-
T
, and radium 223) and any prostate cancer treatments (mCRPC, hormonal, and corticosteroid treatments) between patients initiated on either AA or
Weighted Kaplan-Meier and Cox proportional hazard models were used to compare the combined duration of mCRPC treatments (AA, ENZ, chemotherapy,
sipuleucel
-
T
, and radium 223) and any prostate cancer treatments (mCRPC, hormonal, and corticosteroid treatments) between patients initiated on either AA or
pjoshea13
in
Advanced Prostate Cancer
8 years ago
Progressing metastatic prostate cancer
Then first evidence of bone mets, PSA 0.29, Bicalutamide stopped but gaserelin acetate continued, immediately followed by
Sipuleucel
-
T
.
Then first evidence of bone mets, PSA 0.29, Bicalutamide stopped but gaserelin acetate continued, immediately followed by
Sipuleucel
-
T
.
Hidden
in
Advanced Prostate Cancer
8 years ago
1
2
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
32 results
Fight Prostate Cancer
1 result
Sort by
Most Relevant
Newest